Navigation Links
MannKind to Present at the Wachovia 2008 Healthcare Conference
Date:1/25/2008

VALENCIA, Calif., Jan. 25 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Wachovia Healthcare Conference on January 30, 2008 at 2:00 PM ET at the Langham Hotel in Boston, MA.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at http://www.mannkindcorp.com. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 25, 2017 , ... LabRoots , the leading provider of ... around the world, is announcing a new textbook scholarship, the second scholarship in the ... students, 17 years or older, pursuing a degree in one of the life sciences. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Patient Monitoring and ... Wi-Fi connectivity to reduce the amount of wiring in a healthcare facility and ... mobile devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, and other ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... its 20th anniversary, marking the occasion with a strong presence at Bio-IT World ... Reception and further extends an invitation to all attendees to view posters ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... Works as Vice President of Clinical Operations. She brings years of expertise ... Yaupon Therapeutics. From her professional foundation as a licensed occupational therapist, through a ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):